Skip to content

Pfizer/BioNTech add Germany to large-scale study of COVID-19 vaccine

September 8, 2020

Pfizer (NYSE:PFE) development partner BioNTech (NASDAQ:BNTX) announces regulatory sign-off in Germany for its Phase 2/3 clinical trial evaluating COVID-19 vaccine candidate BNT162b2.

The companies say more than 25K participants have been enrolled thus far, 83% of the target of 30K across 120 sites globally.

https://seekingalpha.com/news/3612059-pfizer-biontech-add-germany-to-large-scale-study-of-covidminus-19-vaccine

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: